↓ Skip to main content

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration

Overview of attention for article published in BMC Medicine, March 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)

Mentioned by

policy
1 policy source
twitter
4 tweeters

Citations

dimensions_citation
64 Dimensions

Readers on

mendeley
60 Mendeley
Title
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration
Published in
BMC Medicine, March 2016
DOI 10.1186/s12916-016-0588-4
Pubmed ID
Authors

Caroline A. Sabin, Peter Reiss, Lene Ryom, Andrew N. Phillips, Rainer Weber, Matthew Law, Eric Fontas, Amanda Mocroft, Stephane de Wit, Colette Smith, Francois Dabis, Antonella d’Arminio Monforte, Wafaa El-Sadr, Jens D. Lundgren

Abstract

In March 2008, the D:A:D study published results demonstrating an increased risk of myocardial infarction (MI) for patients on abacavir (ABC). We describe changes to the use of ABC since this date, and investigate changes to the association between ABC and MI with subsequent follow-up. A total of 49,717 D:A:D participants were followed from study entry until the first of an MI, death, 1 February 2013 or 6 months after last visit. Associations between a person's 10-year cardiovascular disease (CVD) risk and the likelihood of initiating or discontinuing ABC were assessed using multivariable logistic/Poisson regression. Poisson regression was used to assess the association between current ABC use and MI risk, adjusting for potential confounders, and a test of interaction was performed to assess whether the association had changed in the post-March 2008 period. Use of ABC increased from 10 % of the cohort in 2000 to 20 % in 2008, before stabilising at 18-19 %. Increases in use pre-March 2008, and subsequent decreases, were greatest in those at moderate and high CVD risk. Post-March 2008, those on ABC at moderate/high CVD risk were more likely to discontinue ABC than those at low/unknown CVD risk, regardless of viral load (≤1,000 copies/ml: relative rate 1.49 [95 % confidence interval 1.34-1.65]; >1,000 copies/ml: 1.23 [1.02-1.48]); no such associations were seen pre-March 2008. There was some evidence that antiretroviral therapy (ART)-naïve persons at moderate/high CVD risk post-March 2008 were less likely to initiate ABC than those at low/unknown CVD risk (odds ratio 0.74 [0.48-1.13]). By 1 February 2013, 941 MI events had occurred in 367,559 person-years. Current ABC use was associated with a 98 % increase in MI rate (RR 1.98 [1.72-2.29]) with no difference in the pre- (1.97 [1.68-2.33]) or post- (1.97 [1.43-2.72]) March 2008 periods (interaction P = 0.74). Despite a reduction in the channelling of ABC for patients at higher CVD risk since 2008, we continue to observe an association between ABC use and MI risk. Whilst confounding cannot be fully ruled out, this further diminishes channelling bias as an explanation for our findings.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 59 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 27%
Student > Master 11 18%
Student > Ph. D. Student 7 12%
Other 6 10%
Unspecified 6 10%
Other 14 23%
Readers by discipline Count As %
Medicine and Dentistry 34 57%
Unspecified 10 17%
Mathematics 3 5%
Biochemistry, Genetics and Molecular Biology 3 5%
Immunology and Microbiology 3 5%
Other 7 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2019.
All research outputs
#3,425,263
of 13,441,497 outputs
Outputs from BMC Medicine
#1,526
of 2,135 outputs
Outputs of similar age
#73,679
of 265,149 outputs
Outputs of similar age from BMC Medicine
#1
of 1 outputs
Altmetric has tracked 13,441,497 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 2,135 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.1. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,149 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them